Objective: To study the role of long noncoding RNAs as potential biomarkers in heart disease. Methods and Results: Global transcriptomic analyses were done in plasma RNA from patients with or without left ventricular remodeling after myocardial infarction. Regulated candidates were validated in 3 independent patient cohorts developing cardiac remodeling and heart failure (788 patients). The mitochondrial long noncoding RNA uc022bqs.1 (LIPCAR) was downregulated early after myocardial infarction but upregulated during later stages. LIPCAR levels identified patients developing cardiac remodeling and were independently to other risk markers associated with future cardiovascular deaths. 
T he existence of extracellular nucleic acids has been known for several decades. 1 A diagnostic potential of RNA in body fluids was realized after the initial discovery of specific extracellular RNAs in plasma of patients with cancer. 2, 3 Long noncoding RNAs (lncRNAs) are conventionally defined as a transcript longer than 200 nucleotides in length with lack of protein-coding capability. 4 Recognition of the roles of lncRNA in human disease has unveiled new mechanistic understanding and will lead to novel diagnostic and therapeutic approaches. 5 lncRNAs often form secondary structures and are relatively more stable, which facilitate their detection as free nucleic acids in body fluids such as urine and blood. 6 Because of their well-established association with various cancers, lncRNAs have been investigated previously for their potential role as cancer biomarkers in body fluids. A prostate-specific long intergenic noncoding RNA PCA3 in urine has been identified as the most specific biomarker for the detection of prostate cancer with higher specificity compared with the widely used prostate-specific antigen test. 7, 8 The PCA3 assay has been approved for detection of prostate cancer and is readily available for clinical use. In addition, several other studies have highlighted the potential of lncRNAs as candidate biomarkers for the detection of various cancers.
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Although numerous studies (albeit with a relatively small number of patients, with few exceptions) have investigated small RNAs such as microRNAs as potential biomarkers for heart failure (HF), 12 the diagnostic use of circulating lncRNAs in heart diseases has never been investigated. We here explored the potential use of circulating lncRNAs in plasma as prognostic biomarkers for HF. The initial lncRNA screening was performed according to the level of left ventricular (LV) remodeling in a prospective echocardiographic study of patients after myocardial infarction (MI). LV remodeling, which remains frequent in modern clinical practice, 13 is indeed a well-known surrogate of HF after MI. 14 The lncRNA associated with LV remodeling was tested for its association with HF and for its prognostic value in two additional independent populations of patients with systolic HF.
Methods
Populations of Patients With HF
The strategy of lncRNA screening and validation is depicted in Figure 1A . A potential association between detectable lncRNAs in EDTA-plasma and presence of future LV remodeling post MI was analyzed in the REmodelage VEntriculaire (REVE)-2 cohort. This prospective multicenter study was designed to analyze the association between circulating biomarkers and LV remodeling. 15 A total of 246 patients with a first anterior wall Q-wave MI have been enrolled from February 2006 to September 2008. Inclusion criteria were hospitalization within 24 hours after symptom onset and ≥3 akinetic LV segments in the infarct zone at the predischarge echocardiography. Exclusion criteria were inadequate echocardiographic image quality, life-limiting noncardiac disease, significant valvular disease, or prior Q-wave MI. The protocol required serial echographic studies at hospital discharge (days 3-7) and 3 and 12 months after MI to assess presence of LV remodeling, which was defined as a >20% change in LV end-diastolic volume (LVEDV) between baseline and 1 year. Serial blood samples were taken at discharge (days 3-7) and 1, 3, and 12 months after MI. The Institutional Ethics Committee (Center Hospitalier Universitaire de Lille) approved the study; written informed consent was obtained from all patients. For patient characteristics, see Table 1 .
The association between the selected lncRNAs and HF characteristics and prognosis was then analyzed in 2 additional patient populations; these patients were selected from a consecutive series of patients with systolic HF (LV ejection fraction [LVEF] ≤45%) addressed to the Cardiology Department at Lille University. Patients who were ambulatory and clinically stable for ≥2 months underwent blood sampling for the study of prognostic biomarkers. The Institutional Ethics Committee (Center Hospitalier Universitaire de Lille) approved the study; written informed consent was obtained from all patients. The design of this study has been published previously in detail. 16, 17 We first analyzed lncRNAs levels in 344 consecutive patients included from January 2006 to May 2010 (referred to as the HF cohort study). A follow-up was performed after 3 years to assess clinical outcome. For patient characteristics, see Table 2 . The prognostic value of the lncRNA was further assessed in an independent population of 198 patients included between November 1998 and December 2005 who underwent a prognostic evaluation, including a clinical evaluation, echocardiography, cardiopulmonary exercise tests, and B-type natriuretic peptide (BNP) measurement (referred to as the HF case-control study). We selected 99 patients who died from cardiovascular death within 3 years after prognostic evaluation (cases); these 99 patients were matched (for age, sex, and HF pathogenesis) with 99 patients with HF who were alive after 3 years (controls). For patient characteristics, see Table 3 .
RNA Isolation From Plasma, Microarray Analysis of lncRNAs, and lncRNA Stability Testings
This has been described in the Online Data Supplement.
Statistical Analysis
Data were analyzed using R Statistical Package version 3.0. Results are presented as the mean±SD or number (percentages) of patients.
In all statistical analyses, lncRNA levels were log-transformed by taking the base 2 logarithm to account for the skewness of their distributions. Continuous variables were compared using unpaired Student t test. Discrete variables were compared using χ 2 analysis. A P value <0.05 was considered statistically significant. Multivariate logistic regression was used to calculate odds ratios (ORs) and corresponding 95% confidence intervals. ORs were reported for a SD increase. The associations of the baseline levels of the 7-candidate lncRNAs with LV remodeling in the REVE-2 study were assessed using a logistic regression adjusted for age, sex, and LVEDV at baseline. In both HF populations, cardiovascular death was defined as deaths from cardiovascular causes, urgent transplantations (defined as United Network for Organ Sharing status one), or urgent LV assist device implantation. The association of the selected lncRNA with the risk of cardiovascular death was assessed using a logistic regression adjusted for age, sex, ischemic pathogenesis, and diabetes mellitus. In the case-control study, the independent prognostic value of the selected lncRNA was assessed by a logistic regression adjusted for age, sex, ischemic pathogenesis, diabetes mellitus, New York Heart Association class, LVEF, BNP, and peak exercise oxygen consumption (peak VO 2 ). To illustrate the prognostic impact of the selected lncRNA in patients with HF, its levels were categorized into quartiles. Finally, we examined whether the selected lncRNA improved the prediction of cardiovascular death when added to a model with age, sex, HF pathogenesis, diabetes mellitus, New York Heart Association class, LVEF, VO 2 , and BNP, by computing difference in C index (ΔC index), continuous net reclassification improvement and integrated discrimination improvement.
Results
Levels of Circulating lncRNAs Are Altered During the Early Stage of Post-MI LV Remodeling
lncRNA arrays were performed from RNA derived from plasma of patients included in the LV remodeling study ( Figure 1A and 1B). The characteristics of the 246 patients included in this study are summarized in Table 1 . One-year echocardiographic follow-up was completed for 226 (92%) patients. LV remodeling, defined as a >20% change in LVEDV between baseline and 12 months, occurred in 87 (38.5%) patients. From this population, we selected 15 male patients with high LV remodeling (change in LVEDV=73±19%) and 15 male patients without LV remodeling (change in LVEDV=−10±10%) with the same LVEDV at baseline (high remodelers 49±11 versus 49±12 mL/m 2 in nonremodelers). In an attempt to study alterations in circulating lncRNAs at early stage of post-MI LV remodeling, microarrays were performed on RNA from plasma of these 30 patients at baseline.
Hierarchical clustering analysis clearly distinguished the 2 groups of patients based on a specific signature of detectable and significantly regulated circulating lncRNAs ( Figure 1B) . A total of 768 lncRNA transcripts were specifically deregulated (550 lncRNA transcripts upregulated and 218 lncRNA transcripts downregulated; each P<0.05) in patients who will develop LV remodeling ( Figure 1B ; Online Table I ). Filtering of all deregulated transcripts for high signal intensity (≥9) and ≥3-fold deregulation yielded 15 lncRNA candidates, of which 7 could be consistently amplified in all individual samples that were used for microarrays. When the abundance of all detectable lncRNAs was correlated to their chromosomal origins, the highest percentage (77.78%) of high abundant lncRNAs (signal intensity ≥9) originated from the mitochondrial genome (chromosome M; compared with 1.3%-4.3% for somatic and sex chromosomes). Thus, the majority of mitochondrial lncRNAs was abundantly present in plasma (Online Table II ). Interestingly, all 7 lncRNAs that could be consistently amplified in all individual samples originate from the mitochondrial genome and all these lncRNAs were significantly downregulated (P<0.05) in the initial microarray analysis. The expression level of these 7-candidate lncRNAs was then assessed by independent real-time polymerase chain reaction in the entire study population of 246 patients C A B Figure 1 . A, Schematic representation of work flow of long noncoding RNA (lncRNA) screening and validation in various populations with heart failure (HF). A total of 1526 samples collected from 246 patients of the REmodelage VEntriculaire (REVE)-2 cohort 15 ; patients with a first anterior wall Q-wave myocardial infarction (MI) screened for left ventricular (LV) remodeling during the 1-year post-MI period and collected during 4 different time points (baseline, after 1, 3, and 12 months), 344 patients with chronic HF, and 198 patients from a case-control study of patients with chronic HF were used in the present study. This approach identified LIPCAR, a long intergenic noncoding RNA predicting cardiac remodeling and survival of patients with HF. Red dots indicate significantly regulated lncRNAs (>2-fold; P≤0.05). Black dots indicate 7 regulated mitochondrial lncRNAs. Black arrow indicates LIPCAR. B, Hierarchical clustering based on levels of circulating lncRNAs in patients with HF with (P1, P2, and P3) or without (P4, P5, and P6) LV remodeling (i). Volcano plot of fold change and corresponding P values for each lncRNA after comparison of the 2 patient groups (remodelers vs nonremodelers) (ii). C, The relationship between circulating lncRNAs at baseline and LV remodeling. Data are given as odds ratios (OR) and 95% confidence interval per 1 SD. LV remodeling is defined as a >20% change in LV end-diastolic volume (LVEDV) from baseline to 1-year follow-up. Analyses were adjusted on age, sex, and baseline LVEDV.
at baseline. Levels of these 7 lncRNAs were correlated positively with each other (Online Table III Figure 1C ). Because both these lncRNAs levels were correlated positively (Online Table III) , we selected uc022bqs.1 (which had the greatest association with LV remodeling) for further analyses. Because of its properties we refer to this lncRNA as LIPCAR in subsequent sections of the article (long intergenic noncoding RNA predicting cardiac remodeling).
LIPCAR Levels Are Increased During Late Stages of Post-MI Remodeling
We next longitudinally studied the level of LIPCAR in plasma samples obtained 1, 3, and 12 months after MI in the patients of the REVE-2 cohort. In the overall study population, there was an increase in LIPCAR levels throughout the 1-year follow-up period. Importantly, as illustrated in Figure 2A , when assessed at 1, 3, and 12 months, LIPCAR levels were significantly higher in patients developing LV remodeling. Thus, in patients with LV remodeling, circulating levels of LIPCAR are downregulated at baseline, but significantly upregulated later on during the development of HF.
LIPCAR Levels Are Elevated in Patients With Chronic HF
Because LIPCAR was upregulated in the late stages of patients developing LV remodeling post MI, we hypothesized that its circulating levels could also be elevated in patients with chronic HF. This was tested in another independent cohort of 344 patients with systolic HF (see Table 2 for patient characteristics). These patients had similar age and sex characteristics compared with the patients of the LV-remodeling study; they also received angiotensin-converting enzyme inhibitors and β-blockers in most cases. HF was of ischemic pathogenesis The levels of BNP were categorized as low (deciles 1, 2, and 3), intermediate (deciles 4, 5, 6, and 7), and high (deciles 8, 9, and 10). ACE indicates angiotensinconverting enzyme; BNP, B-type natriuretic peptide; HF, heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; and VO 2 , peak exercise oxygen consumption. in about half of the cases. These patients had more advanced disease than the patients of the LV-remodeling study as shown by their lower LVEF. As illustrated in Figure 2B , LIPCAR levels were even higher in chronic HF than in patients with ongoing LV remodeling 1 year after MI; this was apparent for patients with not only ischemic HF but also nonischemic HF (both P<0.0001 versus patients with LV remodeling 1 year after MI). We next studied whether LIPCAR levels may be associated with the risk of future cardiovascular events in patients with chronic HF. During a 3-year clinical follow-up, 39 patients with HF with LIPCAR measurements at inclusion died from cardiovascular causes, whereas 254 were still alive after 3 years. LIPCAR levels at inclusion were significantly associated with the risk of cardiovascular death (OR, [ 
LIPCAR as a Prognostic Indicator for Chronic HF
Because the observation that elevated LIPCAR levels may be associated with future cardiovascular death was derived from a population with a limited number of events, we further studied the prognostic value of this potential biomarker in a third population of patients with chronic systolic HF. As explained earlier, this was a case-control study in which case patients died from cardiovascular death within 3 years after prognostic evaluation, whereas controls were still alive after 3 years. As shown in Table 3 , cases had higher New York Heart Association class and BNP levels and lower peak VO 2 . As shown in Figure 2C , LIPCAR levels at the time of prognostic evaluation were higher in case patients than in control patients (P<0.0001). Compared with patients in the first quartile for LIPCAR levels, patients in the third and fourth quartiles had increased cardiovascular mortality (OR, 6.58 [2.76-16 .67] and 13.23 [5.19-36 .8], respectively; both P<0.0001; Table 4 ). In a model adjusting for age, sex, ischemic pathogenesis, diabetes mellitus, New York Heart Association class, LVEF, BNP, and peak VO 2 , the level of LIPCAR used as a continuous variable was an independent predictor of 3-year cardiovascular mortality with an adjusted OR of 4.16 (2.67-6.90; P<0.0001); similar results were obtained when LIPCAR levels were Table IV ).
Discussion
Cardiovascular diseases are the leading cause of death. 18 Despite advances in understanding and treatment of HF, it still has a poor prognosis. 19 Genome-wide screening approaches provided new opportunities to develop novel diagnostic or prognostic markers and to identify novel therapeutic targets. For example, genomic mapping studies have identified lncRNA PCA3 as a prostate cancer-specific gene, 20 which was later found to be the most sensitive biomarker for detection of prostate cancer. 7, 8 Several lncRNA-based biomarkers were identified in subsequent studies for detection of different cancers. [9] [10] [11] However, such clinical studies were never performed in cardiovascular diseases. A recent study has indicated that the myocardial transcriptome is dynamically regulated in advanced HF and the expression profiles of lncRNAs can discriminate failing hearts of different pathologies. 21 In the present study, we performed a genome-wide screen to identify lncRNAs that are differentially present in plasma from patients with or without severe LV remodeling post MI. Hierarchical clustering analysis distinguished the high remodeling from nonremodeling patients based on the circulating lncRNA signature. Interestingly, almost all lncRNAs that originate from mitochondrial genome were downregulated in the microarray analysis at baseline in patients who presented high LV remodeling 12 months after MI. At least 2 of these 7 lncRNA candidates were found to be significantly downregulated in patients with severe LV remodeling after testing in the entire patient cohort, with the strongest association found for uc022bqs.1. Surprisingly, the level of uc022bqs.1 (here referred as LIPCAR) was significantly upregulated in subsequent samples serially collected at 1, 3, and 12 months after MI. Using another independent patient cohort, we found that the level of LIPCAR is upregulated in patients with chronic HF independently of the pathogenesis, and that higher LIPCAR levels were associated with a higher risk of cardiovascular death. The potential of this lncRNA in predicting mortality in patients with HF was further investigated in another population of patients with systolic HF. Results indicate that higher LIPCAR levels are strongly associated with cardiovascular mortality in patients with HF, and that LIPCAR measurement provides independent information on top of classic risk stratification. Results from all patient cohorts are summarized in Online Table V. Rather than performing microarrays directly in patients with HF, our choice was to screen lncRNAs associated with LV remodeling after MI. The degree of LV remodeling can be measured easily using serial imaging techniques and is a major determinant of ischemic HF. 14 In addition, such a strategy allowed us to avoid imbalances in baseline medications between groups because most patients received maximal treatment regardless of the level of remodeling. The fact that patients with chronic HF had higher levels of LIPCAR than patients with LV remodeling is concordant with the more advanced disease of the HF populations.
Recently, it was found that mitochondrial lncRNAs contribute to >70% of the total lncRNA pool of the human left ventricle, 21 suggesting that a good proportion of mitochondrial lncRNAs detected in circulation might come from the heart. However, at the moment, it is not clear whether LIPCAR simply represents ongoing cellular damage or any other pathological processes in cardiomyocytes or serves any specific function in heart. Deep-sequencing-based characterization of exosomal RNA from human plasma revealed that >3% of total exosomal RNA is represented by lncRNAs. 22 Therefore, it is tempting to speculate that similar to microRNAs, lncRNAs or parts of lncRNAs may also circulate in blood in association with microvesicles or bound to proteins.
However, a potential function of the mitochondrial lncRNA LIPCAR in regulating mitochondrial pathways, such as oxidative phosphorylation, and mechanism of lncRNA circulation in blood need to be explored in future studies.
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